Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR8 | P51685 | 4/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | FAAH | O00519 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15634802 | 1.00 | CCR8 (0.68) | CCR8KDM4EALDH1A1S1PR5LMNA | |
| SCHEMBL17104843 | 0.99 | CCR8 (0.67) | CCR8KDM4EALDH1A1S1PR5LMNA | |
| SCHEMBL17048485 | 0.92 | CCR8 (0.65) | CCR8KDM4EALDH1A1S1PR5TDP1 | |
| SCHEMBL17099425 | 0.92 | CCR8 (0.59) | CCR8KDM4EALDH1A1S1PR5LMNA | |
| SCHEMBL17099412 | 0.92 | CCR8 (0.62) | CCR8KDM4EALDH1A1S1PR5FAAH | |
| SCHEMBL17099387 | 0.91 | CCR8 (0.63) | CCR8KDM4EALDH1A1S1PR5MAPT | |
| SCHEMBL17099393 | 0.91 | CCR8 (0.57) | CCR8KDM4EALDH1A1S1PR5HPGD | |
| SCHEMBL17099350 | 0.91 | KDM4E (0.62) | CCR8KDM4EALDH1A1FAAHMAPT | |
| SCHEMBL17099422 | 0.90 | CCR8 (0.62) | CCR8KDM4EALDH1A1S1PR5MAPT | |
| SCHEMBL17104844 | 0.89 | CCR8 (0.64) | CCR8KDM4EALDH1A1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150274657-A1 | PYRROLIDINES | MERCK PATENT GMBH (DE) | 2015-10-01 | — | — | US | disclosed |
| EP-2903966-A1 | PYRROLIDINES | Merck Patent GmbH (DE) | 2015-08-12 | — | — | EP | disclosed |
| WO-2014053210-A1 | PYRROLIDINES | MERCK PATENT GMBH (DE) | 2014-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274657-A1 | PYRROLIDINES | NR4A3, NR0B1, NR0B2 | CCR8 1120/4885KDM4E 2503/4885ALDH1A1 2933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.